50 Supported by research
A 2020 study published on the cover of Nature showed that epigenetic reprogramming safely reversed aging and restored vision in a blind mouse model.
"so in 2020 we published on the cover of Nature magazine that we could reverse aging safely in an animal for the first time, a mouse. We could cure its blindness." (said at 0:01:32)
A landmark December 2020 study from David Sinclair's laboratory, featured on the cover of Nature, demonstrated that adeno-associated virus-mediated expression of three Yamanaka factors (Oct4, Sox2, and Klf4; OSK) in mouse retinal ganglion cells restored youthful DNA methylation patterns and transcriptomes without inducing oncogenesis/pluripotency loss, promoted axon regeneration after optic nerve injury, and reversed vision loss in both a glaucoma mouse model and aged mice. As this is preclinical animal research, the certainty of evidence for clinical human efficacy remains very low.
A study from China demonstrated that epigenetic reprogramming technology can rebuild bone and cartilage in osteoarthritis models.
"There was a Chinese study that came out recently looked very good. They used our technology to rebuild bone and cartilage in osteoarthritis." (said at 0:05:33)
Published research from Chinese institutions demonstrated that local delivery of OSK (Oct4, Sox2, and Klf4) reprogramming factors via an adeno-associated virus (AAV-OSK) mitigated osteoarthritis in murine models. The treatment improved cartilage integrity, reduced pathological subchondral bone thickening, and decreased cellular senescence through partial epigenetic reprogramming. Because the evidence is limited to preclinical animal and in vitro models, the certainty of evidence is very low.
Early embryonic development involves an epigenetic reset that resets the cell's biological age back to zero.
"when we're fertilized, and we've all been fertilized, we wouldn't exist, and then we need to reset this epigenome, the software needs a reset to go back to being young again. And that happens. ... Young, very young embryos are old and then they get reset." (said at 0:07:30)
The speaker's description aligns closely with recent discoveries using epigenetic aging clocks during embryonic development. Profiling of mouse and human prenatal development demonstrated that newly fertilized/early embryonic cells exhibit biological aging markers that subsequently undergo a natural rejuvenation event (a decrease in epigenetic age down to a 'ground zero' state) during early embryogenesis before organismal aging commences.
A 2023 study showed that experimentally disrupting DNA bundling and 3D chromatin loops in mice caused loss of cell identity and accelerated biological aging.
"And we tested this and published it in 2023 and we created a mouse where we could disrupt those loops and bundles and the mouse's cells lost their function. They lost their identity. The nerve cells forgot how to be nerve cells. Uh and the mouse literally got old." (said at 0:08:33)
David Sinclair's group published a 2023 paper in Cell introducing the 'ICE' (inducible changes to the epigenome) mouse model. In this model, inducing non-mutagenic DNA double-strand breaks prompted chromatin-modifying factors to relocalize, causing erosion of 3D epigenetic structure and chromatin organization, loss of cellular identity (exdifferentiation), and accelerated physiological, cognitive, and molecular signs of aging. Because these findings are from animal and in vitro models, the certainty of evidence for human biology is rated very low.
- supports: Loss of epigenetic information as a cause of mammalian aging. (Cell 2023) · cited 637x in the literature
"Using a system called "ICE" (inducible changes to the epigenome), we find that the act of faithful DNA repair advances aging at physiological, cognitive, and molecular levels, including erosion of the epigenetic landscape, cellular exdifferentiation, senescence, and advancement of the DNA methylation clock, which can be reversed by OSK-mediated rejuvenation." (abstract, results, passage verified)
pubmedfull study (doi)
TET enzymes produce proteins that strip chemical modifications off DNA and are required for epigenetic age resets.
"There are genes called TETs uh which make proteins that strip away chemicals off DNA. These are key to the epigenome reset in embryos as well as in our bodies. And we can get rid of them or inhibit them with a chemical um and we can feed those to the mice or give it to the cells." (said at 0:13:20)
The speaker's statement accurately reflects published research on TET (Ten-Eleven Translocation) enzymes. TET enzymes are methylcytosine dioxygenases that oxidize 5-methylcytosine to initiate active DNA demethylation, removing methyl groups from DNA. They are critical for global epigenetic reprogramming in early embryos and have been shown in preclinical mouse and cell models to be required for partial reprogramming (OSK factor expression) to restore youthful DNA methylation patterns and tissue function. Because the evidence for adult tissue epigenetic resets relies on preclinical animal and in vitro studies, the certainty is low.
In vivo expression of all four original Yamanaka factors (OSKM) leads to tissue dysfunction, teratoma/cancer formation, or death in animals.
"Professor Yamanaka won the Nobel Prize for making cells go back to age zero and making them into stem cells. But that's not going to help us. We don't want to strip away the identity of all our cells. We die within a couple of days. And in fact if you do that to an animal, it tragically does die or gets cancer." (said at 0:15:26)
Studies of in vivo reprogramming in mice have demonstrated that sustained expression of the four Yamanaka factors (Oct4, Sox2, Klf4, c-Myc; OSKM) causes loss of somatic cell identity (dedifferentiation), multi-organ failure, and widespread formation of teratomas/tumors across various tissues. To avoid teratoma formation and premature death, researchers subsequently developed transient or partial reprogramming protocols (e.g., short-term cyclic OSKM expression or omitting Myc/Sox2). Because the evidence is derived entirely from animal models and preclinical systems, the certainty is graded as very low.
- supports: Reprogramming in vivo produces teratomas and iPS cells with totipotency features. (Nature 2013) · cited 558x in the literature
"Here we show that transitory induction of the four factors Oct4, Sox2, Klf4 and c-Myc in mice results in teratomas emerging from multiple organs, implying that full reprogramming can occur in vivo. Analyses of the stomach, intestine, pancreas and kidney reveal groups of dedifferentiated cells that express the pluripotency marker NANOG, indicative of in situ reprogramming." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Transient transcription factor (OSKM) expression is key towards clinical translation of in… (EMBO molecular medicine 2017) · cited 27x in the literature
"However, a number of these reports have described the generation of teratomas caused by sustained reprogramming, which precludes the therapeutic translation of this technology." (abstract, passage verified)
pubmedfull study (doi)
Excluding the c-Myc gene from the Yamanaka factor cocktail allows cells to reset biological age by approximately 75% without losing cell identity or becoming tumorigenic.
"We tried a subset, just three of the Yamanaka genes, and leaving one of these Yamanaka genes out was key. Without that final gene, it's called c-Myc, we call it M, without M, the M gene, cells don't go back 100%. They go back about 75 and stop. And that was the breakthrough." (said at 0:16:10)
Published preclinical research from the speaker's laboratory (Lu et al., 2020; Yang et al., 2023) demonstrates that delivering three of the four Yamanaka factors (Oct4, Sox2, and Klf4, or OSK)—intentionally omitting the oncogene c-Myc—enables partial epigenetic reprogramming. This OSK cocktail restores youthful DNA methylation patterns, transcriptomes, and tissue function (e.g., in injured or aged mouse retinal ganglion cells) without driving cells into a fully dedifferentiated pluripotent state or inducing teratoma/tumor formation. Because the evidence is restricted to mouse models and in vitro systems, the GRADE certainty is very low.
- supports: Reprogramming to recover youthful epigenetic information and restore vision. (Nature 2020) · cited 852x in the literature
"Using the eye as a model CNS tissue, here we show that ectopic expression of Oct4 (also known as Pou5f1), Sox2 and Klf4 genes (OSK) in mouse retinal ganglion cells restores youthful DNA methylation patterns and transcriptomes, promotes axon regeneration after injury, and reverses vision loss in a mouse model of glaucoma and in aged mice." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Sustained Vision Recovery by OSK Gene Therapy in a Mouse Model of Glaucoma. (Cellular reprogramming 2023) · cited 31x in the literature
"Previously, we developed a novel epigenetic rejuvenation therapy, based on the expression of the three transcription factors Oct4 , Sox2 , and Klf4 (OSK), which safely rejuvenates RGCs without altering cell identity in glaucomatous and old mice after 1 month of treatment." (abstract, results, passage verified)
pubmedfull study (doi)
The total length of uncoiled DNA within a single human cell is approximately six feet long.
"every cell has to compact the DNA cuz it's 6 ft long, has to fit into a microscopic little ball." (said at 0:07:41)
The total length of uncoiled genomic DNA in a single diploid human cell is approximately 2 meters (roughly 6 to 6.6 feet), containing approximately 6 billion base pairs spaced at 0.34 nm intervals. This extensive polymer is compacted through association with histones and higher-order chromatin folding to fit inside a cell nucleus typically measuring 5 to 10 micrometers in diameter.
Shinya Yamanaka won the Nobel Prize for discovering how to reprogram mature specialized cells back into pluripotent stem cells.
"Professor Yamanaka won the Nobel Prize for making cells go back to age zero and making them into stem cells." (said at 0:15:26)
Dr. Shinya Yamanaka was awarded the 2012 Nobel Prize in Physiology or Medicine (jointly with Sir John B. Gurdon) for discovering that mature specialized cells (such as fibroblasts) can be reprogrammed into induced pluripotent stem cells (iPSCs) using specific transcription factors.
Tea and coffee contain polyphenols that activate protective enzymes in the human body.
"Actually, tea and coffee are both very good for you because they contain other molecules like polyphenols that again can activate these enzymes that protect us." (said at 0:34:24)
Tea and coffee are well-established dietary sources of bioactive polyphenolic compounds (such as epigallocatechin gallate in green tea and chlorogenic acids in coffee). Scientific reviews and experimental data show that dietary polyphenols modulate endogenous protective enzymes and enhance antioxidant defense pathways in the body.
- supports: The role of polyphenols in modern nutrition. (Nutrition bulletin 2017) · cited 541x in the literature
"Polyphenols are found in plant-based foods and beverages, notably apples, berries, citrus fruit, plums, broccoli, cocoa, tea and coffee and many others... Despite extensive research, the exact mechanisms of action of polyphenols in the human body have not been decisively proven, but there is strong evidence that some targets such as nitric oxide metabolism, carbohydrate digestion and oxidative enzymes are important for health benefits." (abstract, results)
pubmedfull study (doi) - supports: Polyphenols: Chemistry, bioavailability, bioactivity, nutritional aspects and human health… (International journal of biological macromolecules 2024) · cited 158x in the literature
"Polyphenols, including phenolics, alkaloids, and terpenes, are secondary metabolites that are commonly found in fruits, vegetables, and beverages, such as tea, coffee, wine, chocolate, and beer... Complex polyphenols, such as melanin, tannins, and ellagitannins, can promote gut microbiota balance, bolster antioxidant defense, and improve overall human health." (abstract, results)
pubmedfull study (doi)
The CALERIE trial showed that calorie restriction in humans improved health biomarkers with lasting effects, including on the epigenome.
"There was the CALERIE study that showed that you could improve a lot of health biomarkers in humans over that time that had lasting effects including on the epigenome" (said at 0:36:19)
The CALERIE (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) phase 2 trial evaluated a 2-year calorie restriction intervention in healthy, non-obese adults. The trial demonstrated improvements across numerous cardiometabolic risk factors, inflammatory markers (e.g., TNF-alpha), and thyroid hormones. Furthermore, analysis of DNA methylation in trial participants published in 2023 demonstrated that 2 years of calorie restriction significantly slowed the epigenetic pace of aging (measured by DunedinPACE).
In the University of Wisconsin calorie restriction study led by Rozalyn Anderson, rhesus monkeys lived longer and had significantly lower incidence of cancer and overall disease burden.
"The University of Wisconsin where the other lab is, uh, Rozalyn Anderson is the professor that I originally trained what is it 20 years ago. Uh she runs the study now and her monkeys lived longer and they also definitely incontrovertible uh evidence that they had less cancer and I think heart disease but definitely overall disease burden in these monkeys was lower and they lived slightly longer" (said at 0:37:22)
The claim accurately reflects the published findings from the University of Wisconsin calorie restriction study in rhesus macaques (co-authored and led in later years by Rozalyn Anderson). In this longitudinal trial, adult-onset caloric restriction significantly lowered age-related mortality, reduced overall disease burden, and specifically reduced the incidence of cancer, diabetes, cardiovascular disease, and brain atrophy. Because the evidence comes from non-human primate research rather than human clinical outcomes, the certainty of evidence is graded as very low.
- supports: Caloric restriction delays disease onset and mortality in rhesus monkeys. (Science (New York, N.Y.) 2009) · cited 2291x in the literature
"In a population of rhesus macaques maintained at the Wisconsin National Primate Research Center, moderate CR lowered the incidence of aging-related deaths. At the time point reported, 50% of control fed animals survived as compared with 80% of the CR animals. Furthermore, CR delayed the onset of age-associated pathologies. Specifically, CR reduced the incidence of diabetes, cancer, cardiovascular disease, and brain atrophy." (abstract, passage verified)
pubmedfull study (doi) - supports: Caloric restriction improves health and survival of rhesus monkeys. (Nature communications 2017) · cited 860x in the literature
"In the late 1980s two parallel studies were initiated to determine the effect of CR in rhesus monkeys. The University of Wisconsin study reported a significant positive impact of CR on survival, but the National Institute on Aging study detected no significant survival effect." (abstract, passage verified)
pubmedfull study (doi)
A study in mice by Rafael de Cabo at the NIH showed that mice eating within a restricted time window lived substantially longer than mice eating continuously, regardless of macronutrient composition.
"The friend that I mentioned earlier, Rafael de Cabo down at the NIH here in the US. What he did again in mice, but I think there's a lot of evidence that it would translate to humans. He gave mice roughly the same amount of calories, but he gave it to them all day and they had to gobble it all down quickly. It didn't matter what they were eating. It was different amounts of protein, uh carbohydrate, fat. He was hoping to find the optimal diet, but he found that the group that ate within that window lived substantially longer than the ones that ate continuously." (said at 0:39:50)
The speaker accurately describes a 2018/2019 study led by Rafael de Cabo at the National Institute on Aging (NIH), published in Cell Metabolism. The study tested male mice fed diets with different macronutrient compositions under ad libitum (continuous), calorie restriction, or single-meal feeding (MF) regimens matching ad libitum caloric intake. The single-meal fed mice ate their food rapidly, imposing daily fasting periods, and lived significantly longer with reduced morbidity compared to continuously eating mice, independent of dietary macronutrient composition. Because the evidence is from animal models, the GRADE certainty for translation to human longevity is very low.
The branched-chain amino acids valine, isoleucine, and leucine are found in greater abundance in animal protein than in plant protein.
"Valine, isoleucine, leucine. These are three of the 20 amino acids that are found in more abundance in animals than in plants." (said at 0:41:28)
The branched-chain amino acids (BCAAs)—leucine, isoleucine, and valine—are essential amino acids that are generally present in higher concentrations in animal-derived proteins (such as dairy, eggs, and meat) compared to most plant proteins (such as soy, wheat, and legumes). Published nutritional reviews and compositional analyses consistently demonstrate that animal proteins provide a higher density of BCAAs, particularly leucine, per gram of protein compared to plant sources.
Animal studies show that feeding higher amounts of branched-chain amino acids results in shorter lifespan compared to lower amounts.
"And when you give animals a lot of these branched-chain amino acids, uh they live shorter than if you give them less." (said at 0:41:37)
The claim is supported by rodent experiments directly testing the effects of branched-chain amino acid (BCAA) intake on longevity. Feeding mice high-BCAA diets leads to hyperphagia, obesity, and shortened lifespan, whereas lifelong dietary restriction of BCAAs (or specific BCAAs such as isoleucine) extends lifespan and reduces frailty in male mice. Because the body of evidence addressing this specific claim consists entirely of animal model studies, certainty is graded as very low.
- supports: Branched chain amino acids impact health and lifespan indirectly via amino acid balance an… (Nature metabolism 2019) · cited 342x in the literature
"Here, we show that when dietary BCAAs are varied against a fixed, isocaloric macronutrient background, long-term exposure to high BCAA diets leads to hyperphagia, obesity and reduced lifespan." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Lifelong restriction of dietary branched-chain amino acids has sex-specific benefits for f… (Nature aging 2021) · cited 273x in the literature
"Here, we demonstrate that restricting dietary BCAAs increases the survival of two different progeroid mouse models, delays frailty and promotes the metabolic health of wild-type C57BL/6J mice when started in midlife, and leads to a 30% increase in lifespan and a reduction in frailty in male, but not female, wild-type mice when fed lifelong." (abstract, results, passage verified)
pubmedfull study (doi)
Animals with higher mTOR activity have shorter lifespans than animals with less active mTOR.
"we know that animals that have active mTOR live shorter than those that have less active mTOR." (said at 0:43:50)
Extensive experimental evidence in animal models (including yeast, nematodes, fruit flies, and mice) demonstrates that downregulating mTOR signaling—via genetic reduction or pharmacological inhibition (e.g., rapamycin)—significantly extends lifespan. For example, mTOR hypomorphic mice with approximately 25% of wild-type mTOR expression exhibit an approximately 20% increase in median survival compared to control animals. Because the evidence is based on animal models, certainty is rated as very low under GRADE criteria.
Cardiorespiratory fitness measured by VO2 max is correlated with longer human lifespan.
"We know VO2 max is correlated with very long life." (said at 0:44:57)
Cardiorespiratory fitness (CRF), assessed by maximal aerobic capacity or peak metabolic equivalents (a direct surrogate/measure of VO2 max), is consistently and strongly associated with reduced all-cause mortality and increased survival in observational cohorts and meta-analyses. A meta-analysis of 33 cohort studies encompassing 102,980 individuals found that each 1-MET increase in fitness was associated with a 13% reduction in all-cause mortality, and individuals with low CRF had a 70% higher risk of death compared to those with high CRF. Additionally, a large cohort study of 122,007 adults demonstrated an inverse dose-response relationship between cardiorespiratory fitness and long-term mortality across the entire fitness spectrum, with elite performers exhibiting an 80% reduction in risk-adjusted all-cause mortality compared to those in the lowest fitness quartile.
David Sinclair's lab published research in 2003 demonstrating that resveratrol directly activates the SIRT1 enzyme.
"So you can either take resveratrol, and that we showed in 2003—long time ago, I'm old—activates SIRT1 directly. So the enzyme is removing chemicals from the epigenome and making it stable, and it can do it slowly." (said at 0:57:13)
David Sinclair's lab and collaborators published a study in Nature in 2003 (Howitz et al.) showing that resveratrol acts as a small-molecule activator of SIRT1 by lowering the Michaelis constant (Km) of the enzyme for both acetylated substrate and NAD+.
A Pfizer research team published a paper in 2010 claiming that resveratrol activation of SIRT1 was an experimental artifact.
"The controversy that came up was that Pfizer, a team at Pfizer—not the whole company, just a group in the company—put out a paper in 2010 that said resveratrol doesn't do this. It must be an artifact. It's doing something else that makes it look like this." (said at 0:57:41)
A 2010 study published by researchers at Pfizer (Pacholec et al., Journal of Biological Chemistry) evaluated resveratrol and synthetic SIRT1 activators. The authors found that resveratrol only activated SIRT1 in assays using substrates containing a covalently attached fluorophore, and failed to activate SIRT1 against native peptide or full-length protein substrates, concluding that direct SIRT1 activation was an assay artifact.
- supports: SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. (The Journal of biological chemistry 2010) · cited 908x in the literature
"SRT1720, its structurally related compounds SRT2183 and SRT1460, and resveratrol do not lead to apparent activation of SIRT1 with native peptide or full-length protein substrates, whereas they do activate SIRT1 with peptide substrate containing a covalently attached fluorophore. Employing NMR, surface plasmon resonance, and isothermal calorimetry techniques, we provide evidence that these compounds directly interact with fluorophore-containing peptide substrates." (abstract, results, passage verified)
pubmedfull study (doi)
David Sinclair's group published a 2013 Science paper identifying the specific amino acid mechanism by which resveratrol directly activates SIRT1.
"So we then spent 3 years testing that and found exactly how it works to the atomic level. We could even block it by changing an amino acid in this protein... But in scientific circles, everyone's read our Science paper from 2013 and it's not debated." (said at 0:57:55)
In 2013, David Sinclair's laboratory and collaborators published a paper in Science (Hubbard et al.) identifying that allosteric activation of SIRT1 by sirtuin-activating compounds (STACs, including resveratrol) requires a specific amino acid, Glu230, located in the N-terminal domain of SIRT1. Mutating this critical residue blocked SIRT1 activation and its downstream metabolic effects.
SIRT1 requires NAD as a co-substrate, transferring the chemical group removed from epigenetic structures to NAD during its enzymatic reaction.
"SIRT1 also can be activated by giving it fuel, which is NAD. SIRT1 chomps with NAD. And in fact, this is not often known: the chemical that it takes off the epigenome structures is donated to NAD. So without NAD, you can't take the chemicals off. And more levels of NAD make it work faster and better." (said at 1:00:05)
The biochemical mechanism described by the speaker is well established. Class III histone/protein deacetylases (sirtuins, including SIRT1) are NAD+-dependent enzymes that couple the removal of an acetyl group from target substrates (such as histones and other epigenetic proteins) with the cleavage of NAD+. During this reaction, the removed acetyl group is transferred to the ADP-ribose moiety of NAD+, yielding deacetylated protein, nicotinamide, and O-acetyl-ADP-ribose.
- supports: Chemistry of gene silencing: the mechanism of NAD+-dependent deacetylation reactions. (Biochemistry 2001) · cited 304x in the literature
"The Sir2 enzyme family is responsible for a newly classified chemical reaction, NAD(+)-dependent protein deacetylation. New peptide substrates, the reaction mechanism, and the products of the acetyl transfer to NAD(+) are described for SIR2. The final products of SIR2 reactions are the deacetylated peptide and the 2' and 3' regioisomers of O-acetyl ADP ribose (AADPR)..." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent info… (The Journal of biological chemistry 2002) · cited 153x in the literature
"Sir2 and several homologues have been shown to be NAD(+)-dependent histone/protein deacetylases. Previously, it was demonstrated that the yeast enzymes catalyze a unique reaction mechanism in which the cleavage of NAD(+) and the deacetylation of substrate are coupled with the formation of O-acetyl-ADP-ribose, a novel metabolite." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The role of NAD+ dependent histone deacetylases (sirtuins) in ageing. (Current drug targets 2006) · cited 64x in the literature
"Class III enzymes depend in their catalysis on NAD(+) and subsequently, O-acetyl ADP ribose and nicotinamide are formed as a consequence of the acetyl transfer." (abstract, results, passage verified)
pubmedfull study (doi)
Function lab testing detects early signals associated with more than 50 types of cancer.
"Function gives you access to more than 160 advanced lab tests spanning hormones, heart health, kidney function, and even detects early signals linked to more than 50 types of cancer." (said at 0:53:44)
Multi-cancer early detection (MCED) blood testing offered through health platforms (such as the Galleri test by GRAIL) evaluates cell-free DNA (cfDNA) methylation patterns to screen for cancer signals. Clinical validation in a large independent cohort of 4,077 participants (CCGA study substudy 3) confirmed that the test detected cancer signals across more than 50 distinct cancer types with 99.5% specificity, though sensitivity was considerably higher in late stages (77.0% in stage III, 90.1% in stage IV) compared to early stages (16.8% in stage I, 40.4% in stage II).
Nicotinamide mononucleotide (NMN) improves health in old mice and extends mouse lifespan, particularly in females.
"We just resubmitted a paper to be published that showed that NMN is very good for the health of old mice and can extend the lifespan of mice, particularly females." (said at 0:55:21)
The claim accurately reflects findings from preclinical rodent research evaluating long-term nicotinamide mononucleotide (NMN) administration. In mice, NMN reduced frailty and improved health parameters, and significantly increased median lifespan by 8.5% in female mice, though not in males. Because the evidence is restricted to animal models, certainty is graded as very low.
Studies demonstrate a correlation between lower NAD levels in muscle and reduced metabolic activity or metabolic syndrome.
"There is a really good study that showed that people who have lower levels of NAD in their muscle, I think it was, are not as metabolically active as those that have higher levels, or they had metabolic syndrome. Anyway, we could check it out, but there is some good correlations between NAD levels and age-related conditions." (said at 1:02:40)
Human and translational studies support the claim that skeletal muscle NAD+ levels correlate with metabolic activity and age-related muscle decline. Research demonstrates that lower NAD+ status in muscle is associated with impaired mitochondrial oxidative phosphorylation, sarcopenia, and metabolic dysregulation, whereas boosting NAD+ precursors (such as NMN or trigonelline) improves muscle insulin sensitivity and mitochondrial/muscle function in humans and model organisms.
- supports: Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. (Science (New York, N.Y.) 2021) · cited 429x in the literature
"In rodents, obesity and aging impair nicotinamide adenine dinucleotide (NAD + ) biosynthesis, which contributes to metabolic dysfunction... These results demonstrate that NMN increases muscle insulin sensitivity, insulin signaling, and remodeling in women with prediabetes who are overweight or obese" (abstract, results)
pubmedfull study (doi) - supports: Trigonelline is an NAD + precursor that improves muscle function during ageing and is redu… (Nature metabolism 2024) · cited 139x in the literature
"Mitochondrial dysfunction and low nicotinamide adenine dinucleotide (NAD + ) levels are hallmarks of skeletal muscle ageing and sarcopenia 1-3 , but it is unclear whether these defects result from local changes or can be mediated by systemic or dietary cues. Here we report a functional link between circulating levels of the natural alkaloid trigonelline, which is structurally related to nicotinic acid 4 , NAD + levels and muscle health in multiple species." (abstract, results, passage verified)
pubmedfull study (doi)
PCSK9 inhibitors are more effective at lowering cholesterol than statins.
"I might switch to a PCSK9 inhibitor because it's more effective" (said at 1:07:11)
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors typically lower low-density lipoprotein cholesterol (LDL-C) by approximately 50% to 60% as monotherapy, which provides equivalent or greater LDL-C reduction than high-intensity statin monotherapy (and substantially greater reduction than standard- or moderate-intensity statins). In a meta-analysis comparing PCSK9 inhibitor monotherapy directly against high-intensity statin regimens, PCSK9 inhibitors produced significantly larger reductions in LDL-C and apolipoprotein B.
Combining a statin with Zetia (ezetimibe) has been shown to be very effective at lowering cholesterol.
"the combination of a statin and Zetia has been shown to be very effective at lowering cholesterol." (said at 1:08:38)
Extensive randomized trial evidence and meta-analyses confirm that combining a statin with ezetimibe (Zetia) produces substantial incremental reductions in low-density lipoprotein (LDL) cholesterol compared to statin monotherapy or dose escalation alone. In the landmark IMPROVE-IT trial (18,144 patients), adding ezetimibe 10 mg to simvastatin 40 mg significantly lowered median LDL cholesterol from 69.5 mg/dL to 53.7 mg/dL (p < 0.001) and reduced major adverse cardiovascular events. Meta-analyses of dozens of randomized trials consistently confirm the superior lipid-lowering efficacy of this combination.
A study of 1,000 people in China showed that oral nattokinase can reduce or remove arterial plaque.
"And then the second one was based on a study that had a thousand people in China. I know it's not the perfect study, but to me it looks like it might be true... They found that there's an enzyme in that stuff that if you swallow it, it can remove, well, at least it looks like it can remove plaque. Hence, nattokinase." (said at 1:11:50)
The speaker's claim accurately describes a 2022 clinical study conducted in China by Chen et al. (PMID 36072877) involving 1,062 participants with atherosclerosis and hyperlipidemia. The study evaluated oral nattokinase at 10,800 FU/day over 12 months and reported a significant reduction in carotid plaque size and carotid intima-media thickness, with improvement rates ranging from 66.5% to 95.4%. However, because the study was an open-label, non-randomized, uncontrolled clinical investigation published in Frontiers in Cardiovascular Medicine, the GRADE certainty for the underlying clinical efficacy remains low.
Carotid intima-media thickness (IMT) measured by ultrasound is an indicator of whole-body cardiovascular status.
"you can actually do your intima-media thickness, which is important. Tell your doctor if they do that, tell me my IMT, and that is a number that will tell you very similarly how you're doing cardiovascularly for your whole body." (said at 1:12:56)
Carotid intima-media thickness (cIMT) measured by ultrasound is a recognized noninvasive marker of subclinical atherosclerosis that is significantly associated with future systemic cardiovascular events, including stroke and myocardial infarction across large prospective cohort studies. A meta-analysis of prospective cohorts confirmed that increases in cIMT definitions are consistently associated with future stroke (HR 1.30–1.32), myocardial infarction (HR 1.27), and overall cardiovascular disease events (HR 1.28–1.36). While cIMT reflects whole-body cardiovascular risk, large individual-participant meta-analyses (such as the USE-IMT collaboration) note that adding routine cIMT to standard risk models (like the Framingham Risk Score) provides only small incremental improvements in 10-year clinical risk reclassification.
- context: Common carotid intima-media thickness measurements in cardiovascular risk prediction: a me… (JAMA 2012) · cited 763x in the literature
"The addition of common CIMT measurements to the Framingham Risk Score was associated with small improvement in 10-year risk prediction of first-time myocardial infarction or stroke, but this improvement is unlikely to be of clinical importance." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Varying Definitions of Carotid Intima-Media Thickness and Future Cardiovascular Disease: A… (Journal of the American Heart Association 2023) · cited 48x in the literature
"After adjusting for age and sex, a 1-SD increase in CCA-IMT was associated with future stroke (hazard ratio [HR], 1.32 [95% CI, 1.27-1.38]), MI (HR, 1.27 [95% CI, 1.22-1.33]), and CVD events (HR, 1.28 [95% CI, 1.19-1.37])." (abstract, results, passage verified)
pubmedfull study (doi)
PDE5 inhibitor erectile dysfunction drugs can alter the immune system to shift from protecting cancer cells to attacking and killing them.
"it was found that these ED drugs are also good for some types of cancer and can change the immune system so that it goes from protecting the cancer to killing it." (said at 1:13:23)
Preclinical studies and randomized human clinical trials demonstrate that phosphodiesterase-5 (PDE5) inhibitors, commonly used for erectile dysfunction (such as tadalafil and sildenafil), can reverse tumor-induced immune suppression. In conditions like head and neck squamous cell carcinoma and melanoma, tumors recruit immunosuppressive cells—primarily myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs)—to protect themselves from immune destruction. PDE5 inhibitors reduce the numbers and suppressive function of these cells while augmenting tumor-specific CD8+ cytotoxic T-cell activation and proliferation, shifting the immune environment toward active anti-tumor immunity.
- supports: Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-… (The Journal of experimental medicine 2006) · cited 758x in the literature
"In several mouse tumor models, PDE5 inhibition reverses tumor-induced immunosuppressive mechanisms and enables a measurable antitumor immune response to be generated that substantially delays tumor progression. In particular, sildenafil, down-regulates arginase 1 and nitric oxide synthase-2 expression, thereby reducing the suppressive machinery of CD11b+/Gr-1+ myeloid-derived suppressor cells (MDSCs) recruited by growing tumors." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tum… (Clinical cancer research : an official journal of the American Association for Cancer Research 2015) · cited 257x in the literature
"Tadalafil treatment was well tolerated and significantly reduced both MDSCs and Treg concentrations in the blood and in the tumor (P < 0.05). In addition, the concentration of blood CD8(+) T cells reactive to autologous tumor antigens significantly increased after treatment (P < 0.05)." (abstract, results)
pubmedfull study (doi) - supports: Tadalafil augments tumor specific immunity in patients with head and neck squamous cell ca… (Clinical cancer research : an official journal of the American Association for Cancer Research 2015) · cited 184x in the literature
"Evasion of immune surveillance and suppression of systemic and tumor-specific immunity is a significant feature of head and neck cancer development. This study demonstrates that a PDE5 inhibitor, tadalafil, can reverse tumor-specific immune suppression in patients with head and neck cancer, with potential for therapeutic application." (abstract, conclusions, passage verified)
pubmedfull study (doi)
A mouse study indicates that reduced blood flow to hair follicles contributes to hair loss.
"so there's a study in mice at least that hints that lack of blood flow to hair follicles is a reason that you lose hair." (said at 1:15:50)
A landmark mouse study by Yano et al. (2001) demonstrated that perifollicular vascularization controls hair follicle size and cycling. Transgenic overexpression of vascular endothelial growth factor (VEGF) stimulated perifollicular angiogenesis, accelerating hair regrowth and increasing hair follicle and shaft size. Conversely, systemic neutralization of VEGF blocked blood vessel growth around follicles, resulting in retarded hair growth and reduced follicle size. Because this evidence is derived solely from preclinical mouse models, the GRADE certainty is very low.
A published study by Andrea Maier from Singapore found that many commercial NMN supplements contained either no NMN or lower doses than claimed.
"the study that was published, it's worth looking at, by Andrea Maier. She's out of Singapore. She found that a lot of the NMN supplements didn't have NMN in it. And if they did, it was a low amount." (said at 1:18:45)
A 2024 study led by Andrea Maier and colleagues evaluated commercially available nicotinamide mononucleotide (NMN) and urolithin A dietary supplements purchased online and in pharmacies. Quantitative testing revealed substantial deviations from label claims (ranging from +28.6% to -100% of labeled content), with several products containing little to no active NMN.
The United States spends close to 20% of its GDP on healthcare while achieving some of the worst healthcare outcomes.
"The US especially is spending close to 20% of GDP on their healthcare and got some of the worst healthcare." (said at 1:21:45)
The speaker's claim is supported in the context of comparative analyses among high-income and peer nations. National health expenditure in the United States accounts for approximately 17% to 18% of GDP (peaking near 20% during the COVID-19 pandemic), far exceeding any other country. Despite this high level of spending, comparative health system evaluations consistently demonstrate that the US underperforms relative to peer high-income countries on key population health indicators, including life expectancy, preventable mortality, and overall healthcare outcomes.
Steve Horvath discovered the epigenetic clock.
"Steve discovered the epigenetic clock." (said at 1:24:28)
Steve Horvath developed and published the seminal multi-tissue epigenetic clock in 2013 based on 353 CpG DNA methylation sites across 51 healthy tissues and cell types.
- supports: DNA methylation age of human tissues and cell types. (Genome biology 2013) · cited 7491x in the literature
"I developed a multi-tissue predictor of age that allows one to estimate the DNA methylation age of most tissues and cell types... I propose that DNA methylation age measures the cumulative effect of an epigenetic maintenance system. This novel epigenetic clock can be used to address a host of questions in developmental biology, cancer and aging research." (abstract, results and conclusions)
pubmedfull study (doi)
Regular sauna bathing several times per week significantly reduces the incidence of heart disease in Finnish men.
"Mostly Nordic men have been studied, less women, but if you do regular what they call sauna bathing in Finland a few times a week, your rate of heart disease can be much less. And that is reproducible" (said at 1:27:42)
Large prospective cohort studies from the Kuopio Ischemic Heart Disease Risk Factor (KIHD) study in Finland demonstrate that frequent sauna bathing is strongly and inversely associated with fatal coronary heart disease, cardiovascular disease, and all-cause mortality in a dose-dependent manner. Middle-aged Finnish men taking 2 to 3 or 4 to 7 sauna sessions per week had substantially lower risks of cardiovascular disease mortality compared to those taking 1 session per week after adjusting for established cardiovascular risk factors. Subsequent analyses extended these findings to women as well.
- supports: Association between sauna bathing and fatal cardiovascular and all-cause mortality events. (JAMA internal medicine 2015) · cited 288x in the literature
"After adjustment for CVD risk factors, compared with men with 1 sauna bathing session per week, the hazard ratio of SCD was 0.78 (95% CI, 0.57-1.07) for 2 to 3 sauna bathing sessions per week and 0.37 (95% CI, 0.18-0.75) for 4 to 7 sauna bathing sessions per week (P for trend = .005). Similar associations were found with CHD, CVD, and all-cause mortality (P for trend ≤.005)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Sauna bathing is associated with reduced cardiovascular mortality and improves risk predic… (BMC medicine 2018) · cited 61x in the literature
"Higher frequency and duration of sauna bathing are each strongly, inversely, and independently associated with fatal CVD events in middle-aged to elderly males and females." (abstract, conclusions, passage verified)
pubmedfull study (doi)
PET scanning research by Harvard scientists identified that adult humans have functional brown fat.
"And then using PET scanning, people at Harvard, some friends of mine discovered that adults can have brown fat on their own bodies as adults." (said at 1:28:48)
In a landmark 2009 study published in The New England Journal of Medicine, Harvard-affiliated researchers at Joslin Diabetes Center (Cypess et al.) analyzed PET-CT scans and tissue biopsies to establish that adult humans possess functionally active brown adipose tissue depots.
Cold exposure and cold plunges stimulate the growth and activation of brown adipose tissue in adults.
"You can get more brown fat by doing cold plunges and being cold." (said at 1:29:02)
Human clinical trials consistently demonstrate that repeated cold exposure activates brown adipose tissue (BAT) and recruits additional brown fat volume and metabolic activity. Experimental protocols using daily cold exposure in both lean and obese adults show significant increases in BAT glucose uptake and non-shivering thermogenesis.
- supports: Cold acclimation recruits human brown fat and increases nonshivering thermogenesis. (The Journal of clinical investigation 2013) · cited 844x in the literature
"Here, we show that a 10-day cold acclimation protocol in humans increases BAT activity in parallel with an increase in nonshivering thermogenesis (NST)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Short-term Cold Acclimation Recruits Brown Adipose Tissue in Obese Humans. (Diabetes 2016) · cited 296x in the literature
"A 10-day cold acclimation period resulted in increased cold-induced glucose uptake in BAT, as assessed by [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Brown fat thermogenesis and cold adaptation in humans. (Journal of physiological anthropology 2025) · cited 11x in the literature
"Cold stress influences BAT in various time spans: acute cold exposure promptly activates BAT to induce NST, which contributes to immediate maintenance of body temperature. Prolonged cold exposure recruits BAT, resulting in increased capacity of NST and improved cold tolerance." (abstract, results, passage verified)
pubmedfull study (doi)
In mice, the ability to generate new brown fat or convert white fat to beige fat declines with advancing age.
"the older you get, the harder it is to make and convert from white to brown or beige. And so my view on that is—and that's true for mice; I'm not sure it's true for people, but let's say it is" (said at 1:29:30)
The speaker's statement that in mice, advancing age impairs the ability to generate brown/beige fat and convert white fat to beige fat is well-supported by experimental animal literature. Multiple rodent studies demonstrate that aging leads to a decline in the browning capacity of white adipose tissue (WAT) and impairs adrenergic- and cold-induced beige adipocyte formation and thermogenic function. Certainty is rated as low because the evidence is restricted to preclinical animal models.
- supports: Impaired adrenergic agonist-dependent beige adipocyte induction in aged mice. (Obesity (Silver Spring, Md.) 2017) · cited 28x in the literature
"Inductive ability of beige adipocytes in WAT declines with aging in mice. It may be partly because of a decreased number of progenitor cells associated with aging." (abstract, conclusions, passage verified)
pubmedfull study (doi) - supports: Differential Responses of White Adipose Tissue and Brown Adipose Tissue to Calorie Restric… (The journals of gerontology. Series A, Biological sciences and medical sciences 2021) · cited 39x in the literature
"We found age-related changes in different types of adipose tissue, including adipocyte enlargement, declined beiging of WAT, and declined thermogenic and β-oxidational function of BAT." (abstract, results)
pubmedfull study (doi) - supports: Aregs-IGFBP3-mediated SMC-like cells apoptosis impairs beige adipocytes formation in aged … (Molecular metabolism 2025) · cited 1x in the literature
"Aging is associated with a decline in the browning capacity of white adipose tissue (WAT), contributing to metabolic dysfunction." (abstract, background, passage verified)
pubmedfull study (doi)
Zetia (ezetimibe) works by blocking the uptake and absorption of cholesterol.
"It is the drug that blocks uptake of cholesterol." (said at 1:08:33)
The statement accurately reflects the well-established pharmacological mechanism of ezetimibe (Zetia). Ezetimibe selectively binds to and inhibits Niemann-Pick C1-Like 1 (NPC1L1), a transport protein situated on the brush border of intestinal enterocytes (and hepatocytes), thereby blocking the cellular uptake and intestinal absorption of dietary and biliary cholesterol.
PDE5 inhibitor erectile dysfunction drugs were originally developed and clinically trialed as a treatment for angina.
"GUEST1: It was an angina medication, wasn't it? HOST: Exactly." (said at 1:14:45)
The speaker's statement is fully supported by published drug-development literature. Sildenafil, the first-in-class phosphodiesterase-5 (PDE5) inhibitor, was originally synthesized and tested in clinical trials as a cardiovascular medication for angina pectoris and hypertension. During clinical testing, side effects and physiological observations led researchers to repurpose PDE5 inhibitors as a primary treatment for erectile dysfunction.
Scientific evidence demonstrates that omega-3 supplementation exerts anti-inflammatory effects.
"The data looks really pretty good that if you have some of that, it's anti-inflammatory." (said at 1:17:26)
A large body of randomized controlled trials and meta-analyses demonstrates that omega-3 polyunsaturated fatty acid (PUFA) supplementation significantly reduces key markers of systemic inflammation, including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α).
- supports: Does omega-3 PUFAs supplementation improve metabolic syndrome and related cardiovascular d… (Critical reviews in food science and nutrition 2024) · cited 87x in the literature
"The meta-analysis demonstrated that omega-3 PUFAs supplementation significantly reduced triglyceride (TG) (WMD: -18.18 mg/dl; 95% CI: -25.41, -10.95; p < 0.001), total cholesterol (TC) (WMD: -3.38 mg/dl; 95% CI: -5.97, -0.79; p = 0.01), systolic blood pressure (SBP) (WMD: -3.52 mmHg; 95% CI: -5.69, -1.35; p = 0.001), diastolic blood pressure (DBP) (WMD: -1.70 mmHg; 95% CI: -2.88, -0.51; p = 0.005), interleukin-6 (IL-6) (WMD: -0.64 pg/ml; 95% CI: -1.04, -0.25; p = 0.001), tumor necrosis factor-α (TNF-α) (WMD: -0.58 pg/ml; 95% CI: -0.96, -0.19; p = 0.004), C-reactive protein (CRP) (WMD: -0.32 mg/l; 95% CI: -0.50, -0.14; p < 0.001), and interleukin-1 (IL-1) (WMD: -242.95 pg/ml; 95% CI: -299.40, -186.50; p < 0.001)" (abstract, results)
pubmedfull study (doi) - supports: The effects of ω-3 fatty acids on inflammatory and oxidative stress markers in patie… (Prostaglandins & other lipid mediators 2024) · cited 9x in the literature
"The meta-analysis of 23 trials, involving 1523 patients, demonstrated a significant decrease in TNF-α (SMD: -1.62, 95 % CI: -2.89 to -0.35, P= 0.013) and increase in TAC (SMD: 0.92, 95 % CI: 0.33-1.52, P = 0.002) following ω-3 fatty acids administration." (abstract, results)
pubmedfull study (doi)
Human infants rely on metabolically active brown adipose tissue for thermogenesis because they cannot initially shiver.
"Babies have brown fat. It's a highly metabolically active type of fat in babies that keeps them warm because they can't shiver initially." (said at 1:28:35)
Human newborns possess substantial depots of metabolically active brown adipose tissue (BAT), which functions as the primary mechanism for thermoregulation through non-shivering thermogenesis mediated by uncoupling protein 1 (UCP1). Newborns have insufficient skeletal muscle mass and neuromuscular maturity to mount an effective shivering response to cold exposure, making BAT-mediated non-shivering thermogenesis essential for maintaining core body temperature.
Steve Horvath discovered the epigenetic clock, which measures chemical changes on DNA over time.
"Steve Horvath discovered the epigenetic clock. For those of you who don't know what that is, it's chemicals on the DNA that change with time." (said at 1:33:36)
Steve Horvath developed the seminal multi-tissue epigenetic clock (published in 2013), an algorithm based on DNA methylation levels (chemical additions of methyl groups to DNA) at 353 CpG sites that correlate tightly with chronological age across diverse human tissues and cell types.
- supports: DNA methylation age of human tissues and cell types. (Genome biology 2013) · cited 7491x in the literature
"I developed a multi-tissue predictor of age that allows one to estimate the DNA methylation age of most tissues and cell types... Finally, I characterize the 353 CpG sites that together form an aging clock in terms of chromatin states and tissue variance. I propose that DNA methylation age measures the cumulative effect of an epigenetic maintenance system. This novel epigenetic clock can be used to address a host of questions in developmental biology, cancer and aging research." (abstract, results and conclusions)
pubmedfull study (doi)
The DunedinPACE aging measure assesses DNA methylation patterns on DNA rather than telomeres.
"No, it's not. I don't believe so. It's just looking at what's called DNA methylation pattern on the DNA." (said at 1:35:05)
The speaker's statement is supported. DunedinPACE (Pace of Aging Calculated from the Epigenome) is an epigenetic biomarker that measures the rate of biological aging by assessing DNA methylation patterns across the genome from a single-time-point blood sample, rather than measuring telomere length.
People taking weight loss drugs like GLP-1 agonists show protection against dementia.
"It looks like there's protection against dementia from those who are on the weight loss drugs." (said at 1:41:03)
Substantial observational cohort studies, pooled randomized trial data, and post hoc trial analyses indicate that glucagon-like peptide-1 (GLP-1) receptor agonists are associated with a reduced incidence of all-cause dementia and Alzheimer's disease, as well as an attenuation of biological dementia risk signatures in adults with overweight or obesity. While dedicated randomized trials testing primary dementia prevention endpoints are ongoing or undergoing evaluation, the current evidence aligns with the speaker's cautious statement that GLP-1 drugs appear protective against dementia.
- supports: Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data f… (Alzheimer's & dementia (New York, N. Y.) 2022) · cited 198x in the literature
"Dementia rate was lower both in patients randomized to GLP-1 RAs versus placebo (hazard ratio [HR]: 0.47 (95% confidence interval [CI]: 0.25-0.86) and in the nationwide cohort (HR: 0.89; 95% CI: 0.86-0.93 with yearly increased exposure to GLP-1 RAs)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a p… (EClinicalMedicine 2024) · cited 71x in the literature
"Instead, after multiple-testing correction, semaglutide was associated with reduced risk for several such outcomes, notably cognitive deficit compared to sitagliptin (HR 0.72, 95% CI 0.64-0.80) and glipizide (HR 0.72, 95% CI 0.63-0.81), dementia compared to sitagliptin (HR 0.52, 95% CI 0.40-0.68)" (abstract, results, passage verified)
pubmedfull study (doi) - supports: Semaglutide attenuates a proteomics-based dementia risk signature in older adults with ove… (Alzheimer's & dementia (Amsterdam, Netherlands) 2026)
"Semaglutide reduced increases in predicted dementia risk versus placebo: 2.5-fold less increase in 5-year risk (26.0% lower predicted event rate; odds ratio [OR] 0.74, 95% confidence interval [CI] 0.65-0.85) and 1.67-fold less increase in 20-year risk (8.8% lower; OR 0.91, 95% CI 0.88-0.94)." (abstract, results, passage verified)
pubmedfull study (doi)
Globally, 1 billion people are obese and half a billion people are starving.
"A billion people that are obese and half a billion people that are starving. It's like the number one leading cause of malnutrition globally is obesity." (said at 1:42:37)
The speaker's figures and characterization closely align with global health surveillance data. A comprehensive 2024 pooled analysis by the NCD Risk Factor Collaboration published in The Lancet (incorporating data from 3,663 population-representative studies with 222 million participants) established that by 2022, over 1 billion people globally were living with obesity (including ~879 million adults and ~159 million children and adolescents). The study also confirmed that obesity has overtaken underweight as the leading form of malnutrition in the vast majority of countries (in 89% of countries for women and 73% for men). Furthermore, global reports by the UN Food and Agriculture Organization (FAO) estimate that between 700 and 800 million people (around 735 million) experience hunger and undernourishment worldwide, placing the speaker's 'half a billion' estimate in the general range.
About 40% of adults in the United States have obesity.
"About 40% of US adults have obesity." (said at 1:43:30)
According to nationally representative surveillance data from the Centers for Disease Control and Prevention's (CDC) National Center for Health Statistics (NHANES), the prevalence of obesity among US adults aged 20 and older is approximately 40% (39.8% in 2015–2016 and 41.9%–42.4% in recent cycles). The speaker's statement accurately reflects national epidemiological data.
Harvard research led by Robert Waldinger demonstrates that mental attitude and social life are as important as, or more important than, blood pressure and cholesterol for health and longevity.
"Robert Waldinger, a Harvard scientist, has found that the mental attitude and your social life is as important as your blood pressure and cholesterol, if not more important." (said at 1:54:29)
Robert Waldinger, director of the Harvard Study of Adult Development, and colleagues have shown across decades of longitudinal data that relational satisfaction and social connection in midlife are stronger predictors of late-life physical health, longevity, and cognitive function than traditional biological markers like midlife cholesterol levels. This is corroborated by landmark meta-analytic data (such as Holt-Lunstad et al., 2010) demonstrating that social integration and relationships have an effect size on mortality risk comparable to or exceeding established biomedical risk factors like hypertension, obesity, and dyslipidemia.
Research in mice shows that a lack of exposure to violet light induces shortsightedness (myopia).
"A friend of mine in Japan found that if you don't see violet light uh and you're a mouse, you get uh shortsightedness." (said at 1:55:45)
Experimental research conducted by Japanese research groups (notably at Keio University) established that violet light (360–400 nm) exposure suppresses and prevents myopia progression in mouse models of lens-induced myopia via retinal neuropsin (OPN5) signaling. In the absence of violet light exposure or OPN5 signaling, mice develop greater myopic refractive shifts and axial elongation. Because the claim specifically concerns findings in a mouse model, certainty is rated very low in accordance with GRADE criteria for preclinical animal evidence.
- supports: Violet light suppresses lens-induced myopia via neuropsin (OPN5) in mice. (Proceedings of the National Academy of Sciences of the United States of America 2021) · cited 146x in the literature
"Recent reports have shown that short-wavelength visible violet light is the component of sunlight that appears to play an important role in preventing myopia progression in mice, chicks, and humans. The mechanism underlying this effect has not been understood. Here, we show that violet light prevents lens defocus-induced myopia in mice. This violet light effect was dependent on both time of day and retinal expression of the violet light sensitive atypical opsin, neuropsin (OPN5)." (abstract, passage verified)
pubmedfull study (doi) - supports: Suppressive effects of violet light transmission on myopia progression in a mouse model of… (Experimental eye research 2023) · cited 32x in the literature
"Exposure to violet light (VL), a short wavelength (360-400 nm) of visible light from sunlight, has been suggested as an effective preventive and suppressive treatments for the development and progression of myopia. However, the clinical application of VL remains unclear. In this study, we aimed to investigate the preventive and suppressive effects of VL on myopia progression. Various transmittances of VL (40%, 70%, and 100%) were tested in C57BL/6J mice with lens-induced myopia (LIM)." (abstract)
pubmedfull study (doi)
There is no scientific evidence that testosterone therapy extends lifespan or promotes longevity.
"He's also done a lot of testosterone work which shows benefits, but it doesn't extend lifespan. There was no evidence that it does that for longevity." (said at 2:00:44)
Multiple meta-analyses of randomized controlled trials (RCTs) and large multicenter trials (such as the TRAVERSE trial) demonstrate that testosterone replacement therapy (TRT) improves specific symptoms of hypogonadism (e.g., sexual function, anemia, lean mass) but has no statistically significant effect on all-cause mortality or cardiovascular mortality compared to placebo. There is no randomized clinical trial evidence showing that TRT extends lifespan or promotes longevity.
- supports: Association between testosterone replacement therapy and cardiovascular outcomes: A meta-a… (Progress in cardiovascular diseases 2024) · cited 26x in the literature
"Pooled analysis of primary and secondary outcomes showed that the incidence of any CVD events (OR, 1.12 (95%CI: 0.77-1.62), P = 0.55), stroke (OR, 1.01 (95%CI: 0.68-1.51), P = 0.94), myocardial infarction (OR, 1.05 (95%CI: 0.76-1.45), P = 0.77), all-cause mortality (OR, 0.94 (95%CI: 0.76-1.17), P = 0.57), and CVD mortality (OR, 0.87 (95%CI: 0.65-1.15), P = 0.31) was comparable between TRT and placebo groups." (abstract, results)
pubmedfull study (doi) - supports: Long-Term Cardiovascular Safety of Testosterone-Replacement Therapy in Middle-Aged and Old… (American journal of cardiovascular drugs : drugs, devices, and other interventions 2025) · cited 7x in the literature
"Placebo and TRT had similar rates of all-cause mortality (RR 0.85; 95% CI 0.60-1.19; p = 0.33). There was a significant increase in the incidence of cardiac arrhythmias (RR 1.53; 95% CI 1.20-1.97; p < 0.01). There was no significant difference between groups in cardiovascular mortality (RR 0.85; 95% CI 0.65-1.12; p = 0.25)" (abstract, results)
pubmedfull study (doi)
Demis Hassabis and his team solved the protein folding problem computationally, enabling 3D structural modeling of thousands of proteins.
"now that um uh Demis Hassabis has and his team, not just him, has cracked the code for protein folding. We now know all the chess pieces. We were guessing and it took years to find out what one chess piece looked like. And there's over 15,000 of these pieces now. These are all now modeled in 3D." (said at 1:50:49)
Demis Hassabis and his team at DeepMind developed AlphaFold, a deep learning system that computationally solved the 50-year-old protein structure prediction problem with atomic accuracy. In 2021, the team published AlphaFold's architecture in Nature and applied it to model nearly the entire human proteome (98.5% of human proteins, comprising roughly 20,000 proteins), providing high-confidence 3D structural predictions for tens of thousands of proteins.
- supports: Highly accurate protein structure prediction with AlphaFold (Nature 2021) · cited 46735x in the literature
"Predicting the three-dimensional structure that a protein will adopt based solely on its amino acid sequence—the structure prediction component of the ‘protein folding problem’ 8 —has been an important open research problem for more than 50 years 9 . Despite recent progress 10–14 , existing methods fall far short of atomic accuracy, especially when no homologous structure is available. Here we provide the first computational method that can regularly predict protein structures with atomic accuracy even in cases in which no similar structure is known." (abstract, results, passage verified)
openalexfull study (doi) - supports: Highly accurate protein structure prediction for the human proteome (Nature 2021) · cited 3289x in the literature
"Here we markedly expand the structural coverage of the proteome by applying the state-of-the-art machine learning method, AlphaFold 2 , at a scale that covers almost the entire human proteome (98.5% of human proteins)." (abstract, results, passage verified)
openalexfull study (doi)
Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.